This announcement is a separate document:
关于自愿披露聚乙二醇伊立替康用于治疗伴脑转移的三阴性乳腺癌II期临床试验完成首例受试者入组的公告
Announcement on voluntary disclosure of polyethylene glycol irinotecan for the treatment of triple-negative breast cancer with brain metastasis completed the enrollment of the first patient
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated